93 related articles for article (PubMed ID: 12050728)
21. [Chemotherapy of non-hodgkin's lymphomas (author's transl)].
Fereberger W; Neubauer M
Acta Med Austriaca; 1981; 8(1):1-6. PubMed ID: 7234308
[TBL] [Abstract][Full Text] [Related]
22. Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas.
Cilley J; Winter JN
Haematologica; 2006 Jan; 91(1):114-20. PubMed ID: 16434379
[TBL] [Abstract][Full Text] [Related]
23. Cladribine in indolent non-Hodgkin's lymphoma.
Sigal DS; Saven A
Expert Rev Anticancer Ther; 2008 Apr; 8(4):535-45. PubMed ID: 18402520
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in indolent and aggressive lymphomas and its influence on disease outcome.
Zodelava M; Betaneli M; Tsartsidze E; Kharabadze M
Georgian Med News; 2009 Feb; (167):32-6. PubMed ID: 19276466
[TBL] [Abstract][Full Text] [Related]
25. [The present status of therapeutic possibilities in malignant lymphomas].
Klener P
Cas Lek Cesk; 1993 May; 132(9):261-5. PubMed ID: 8513471
[TBL] [Abstract][Full Text] [Related]
26. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
27. Autologous stem cell transplantation in treatment of aggressive non-Hodgkin's lymphoma.
Kluin-Nelemans HC
Croat Med J; 2002 Oct; 43(5):561-4. PubMed ID: 12402396
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
29. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
[TBL] [Abstract][Full Text] [Related]
30. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
31. Purine analogue combinations for indolent lymphomas.
Di Bella N; Ravandi F
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S11-21. PubMed ID: 16549109
[TBL] [Abstract][Full Text] [Related]
32. The role of allogeneic transplantation in non-Hodgkin's lymphoma.
Peggs KS; Mackinnon S; Linch DC
Br J Haematol; 2005 Jan; 128(2):153-68. PubMed ID: 15638849
[TBL] [Abstract][Full Text] [Related]
33. Indolent lymphomas other than follicular and marginal zone lymphomas.
Peinert S; Seymour JF
Hematol Oncol Clin North Am; 2008 Oct; 22(5):903-40, viii. PubMed ID: 18954743
[TBL] [Abstract][Full Text] [Related]
34. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.
Sureda A
Hematol Oncol Clin North Am; 2007 Oct; 21(5):943-60. PubMed ID: 17908630
[TBL] [Abstract][Full Text] [Related]
35. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
[TBL] [Abstract][Full Text] [Related]
36. [Lymphoma. Current status and treatment].
Labardini-Méndez JR; Gutiérrez AA; Martínez F; Chávez AD; Morales-Polanco MR; Sobrevilla-Calvo PJ
Gac Med Mex; 2000; 136(3):221-47. PubMed ID: 10893851
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
[TBL] [Abstract][Full Text] [Related]
38. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
39. Analysis of local control in patients with non-Hodgkin's lymphoma according to the WHO classification.
Sakata K; Satoh M; Someya M; Nagakura H; Oouchi A; Nakata K; Kogawa K; Koito K; Hareyama M; Himi T
Strahlenther Onkol; 2005 Jun; 181(6):385-91. PubMed ID: 15925981
[TBL] [Abstract][Full Text] [Related]
40. Management of histologically indolent non-Hodgkin's lymphomas.
Solal-Celigny P
Baillieres Clin Haematol; 1996 Dec; 9(4):669-87. PubMed ID: 9138612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
